摘要
Abstract
Objective To compare the clinical efficacy and safety profile of benzbromarone tablets versus allopurinol tablets in acute cerebral infarction combined with hyperuricemia.Methods A total of 180 patients with acute cerebral infarction combined with hyperuricemia were randomly divided into the control group (n =60 cases),the treatment A group (n =60 cases),the treatment B group (n =60 cases).All three groups were given conventional treatment of cerebral infarction.The control group was given placebo while the treatment A group was given allopurinol 100 mg bid,and the treatment B group was given benzbromarone 50 mg qd.All three groups were treated for 14 days.The clinical efficacy,uric acid (UA),high sensitive C-reactive protein (hs-CRP),interleukin-6 (IL-6),carotid intima-media thickness (IMT),incidence of adverse drug reactions were compared before and after treatment between three groups.Results After treatment,the total effective rates in three groups were 76.67 ％ (46/60 cases),88.33 ％ (53/60 cases),95.00％ (57/60 cases),with significant differences (P ＜ 0.05).After treatment,the main observation indexes in the treatment A group,the treatment B group and the control group:the levels of UA were (237.31 ± 10.63),(162.67 ± 10.12),(586.52 ± 50.60) μmol · L-1;the levels ofhs-CRP were(4.93 ± 0.68),(3.57 ± 1.03),(12.07 ± 0.54) mg · L-1;the levels of IL-6 were (78.31 ± 10.63),(68.67 ± 10.12),(190.52 ± 50.60) pg · mL-1;the levels of IMT were (1.08 ± 0.25),(0.76 ± 0.29),(1.42 ± 0.54) mm,with statistically significant difference (P ＜ 0.05).Compared with treatment A group,the levels of UA,hs-CRP,IL-6,IMT were significantly lower in treatment B group,with significant difference (P ＜ 0.05).No obvious adverse drug reactions occurred in three groups.Conclusion Both benzbromarone and allopurinol were able to markedly alleviate uric acid levels,inflammatory reaction and atherosclerosis with high safety profile,while benzbromarone exerted higher efficacy.关键词
苯溴马隆片/别嘌醇片/脑梗死/高尿酸血症Key words
benzbromarone tablet/allopurinol tablet/cerebral infarction/hyperuricemia分类
医药卫生
